Floridienne (FLOB) Q3 2025 TU earnings summary

Executive summary

• Trends at the end of September 2025 aligned with prior outlook, driven by BIOTROP's outstanding performance, BioFirst's gradual improvement, and positive Food Division results despite ingredient cost pressures.

Segment performance

• BIOTROP achieved over 30% sales and profitability growth in local currency for the first nine months, confirming its strategic importance.

• BioFirst's greenhouse crop activities improved in Q3 after a challenging first half, with profitability recovering due to commercial and cost measures.

• Natix saw higher turnover and profitability, supported by demand for high-value nutrition, pharma, and cosmetics applications; acquired majority stake in Terhormon S.p.A.

• Food Division posted sales growth, led by cold sauces, but faced margin pressure from rising ingredient costs; investments underway to expand production capacity for 2026.

• Chemical Division's SNAM continued developing battery recycling, with profitability weighed by low metal prices; Kimflor remained resilient in volatile markets.

Outlook and guidance

• Confidence in medium-term growth, supported by BioFirst's position in biological control, BIOTROP's momentum, and robust performance in other divisions.

• Anticipated European regulatory changes to accelerate biocontrol solutions are expected to further support BIOTROP's international expansion.